Loading
Life sciences · Journal article
Cellular & Molecular Biology Letters · October 3, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Metabolic reprogramming in prostate cancer (PCa) is a staged reorganization of the specialized citrate-producing metabolism of normal prostate epithelium. Malignant transformation reverses the zinc–citrate axis and restores mitochondrial oxidation, followed by androgen receptor-linked lipid remodeling, nutrient flexibility, and organelle and lineage plasticity. Extracellular vesicles (EVs), particularly exosomes/small extracellular vesicles (sEVs), can externalize aspects of these states by transferring proteins, regulatory RNAs, metabolites, and lipids. Across tumor, stromal, immune, vascular, and metastatic compartments, EV-mediated transfer may redistribute nutrients and reshape bioenergetic, redox, and lipid programs in recipient cells. These processes link intercellular metabolic adaptation to proliferation, angiogenesis, metastasis, therapy resistance, immunosuppression, and tumor microenvironment (TME) remodeling. This review integrates PCa-specific metabolic architecture with EV/sEV cargo selection, transfer, uptake, and recipient-cell responses, emphasizing how these processes generate biological and clinical consequences. Evidence for some proposed EV-metabolism axes remains indirect or emerging, and their interpretation requires evidence-matched claims. By placing EV/sEV signaling within broader intercellular communication networks, we outline implications for biomarkers, disease monitoring, and therapeutic development. EV/sEV-mediated metabolic communication thus offers a biologically grounded view of PCa progression and microenvironmental adaptation.